In conclusion, we were able to demonstrate that LAG-3 expression on TILs at the tumor front of stage II colon cancers was associated with better outcomes in both the overall stage II cohort and within the subgroup of stage II MSS tumors. The gene discussed is LAG3; the disease is malignant colon neoplasm.